AstraZeneca, Merck Report Positive Long-term Data for Lynparza

Seeking Alpha46minutes ago

Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer

BenzingaDec 11 23:16

LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial

BusinesswireDec 11 23:15

Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term

Yahoo FinanceDec 10 22:40

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

Zacks Dec 10 22:05

AstraZeneca (AZN) Receives a Hold From Jefferies

TipRanksDec 10 15:36 · Ratings